(Washington, D.C.) -- The FDA could make a decision Wednesday on Pfizer's COVID booster shots.
An advisory panel already recommended a third dose for those at high risk, along with people 65 and older. It didn't think an extra shot was needed yet for everyone else. The agency often follows the committee's advice.
As for Moderna's booster, that remains under consideration. Johnson and Johnson says its one-shot vaccine is more effective with a second dose.